Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 6/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | BRD4 | O60885 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31355727 | 0.82 | TSHR (0.94) | TSHRL3MBTL1LMNARAB9AHTT | |
| SCHEMBL31355731 | 0.82 | TSHR (0.94) | TSHRL3MBTL1LMNARAB9AHTT | |
| SCHEMBL2077313 | 0.80 | PTK2 (1.00) | TSHRL3MBTL1LMNARAB9AHTT | |
| SCHEMBL23657930 | 0.79 | ALDH1A1 (0.83) | TSHRL3MBTL1LMNARAB9AHTT | |
| SCHEMBL20569319 | 0.77 | MAPK1 (0.70) | TSHRL3MBTL1LMNAHTTALOX15 | |
| SCHEMBL7823939 | 0.77 | LMNA (0.57) | TSHRL3MBTL1LMNARAB9AHTT | |
| SCHEMBL23496567 | 0.77 | BRD4 (1.00) | SMN1; SMN2ALDH1A1MAPTBRD4MEN1 | |
| SCHEMBL20568606 | 0.76 | CYP1A2 (0.45) | TSHRL3MBTL1LMNARAB9AHTT | |
| SCHEMBL7956193 | 0.76 | LMNA (0.56) | TSHRL3MBTL1LMNARAB9AHTT | |
| SCHEMBL13083617 | 0.75 | CYP1A2 (0.50) | TSHRL3MBTL1LMNAHTTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-1054667-B1 | BICYCLIC PYRROLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTIINFLAMMATORY AND IMMUNOMODULATING AGENTS | ASTRAZENECA UK LTD (GB) | 2003-04-16 | — | — | EP | disclosed |
| US-6291507-B1 | INHIBITOR OF MONOCYTE CHEMOATTRACTANT PROTEIN-1; INDOLE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-09-18 | — | — | US | disclosed |
| EP-1054667-A1 | BICYCLIC PYRROLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTIINFLAMMATORY AND IMMUNOMODULATING AGENTS | AstraZeneca UK Limited (GB) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999040913-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, GAA, ALPI | TSHR 4071/4885L3MBTL1 1716/4885LMNA 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.